Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P11021 (
BiP
)
2,049
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In order to determine whether the endoplasmic reticulum (ER) luminal FK506-binding protein,
FKBP13
, shares properties of ER molecular chaperones, MDCK cells were treated with either tunicamycin or Ca2+ ionophores. By Northern-blot analysis, tunicamycin resulted in a 2-fold rise in
FKBP13
mRNA, whereas ionophores (A23187 and ionomycin) caused a more impressive rise in
FKBP13
mRNA (up to 5-fold with ionomycin). Actinomycin D chase experiments in ionomycin-treated cells revealed no change in the half-life of
FKBP13
mRNA, indicating that the increase in
FKBP13
mRNA observed was not due to greater message stability. Moreover, sequencing of the 5' flanking region of the gene for murine
FKBP13
revealed significant similarity to similar regions in human
BiP
(immunoglobulin-binding protein) and the human glucose-regulated protein grp94, including a 37 bp sequence in
FKBP13
with approximately 50% identity with the unfolded protein response element of the
BiP
gene. Together, these data suggest a role for
FKBP13
in ER protein folding.
...
PMID:Induction of the FK506-binding protein, FKBP13, under conditions which misfold proteins in the endoplasmic reticulum. 752 46